Received: 29 March 2018
Accepted: 27 June 2018
First Online: 16 July 2018
Ethics approval and consent to participate
: Not applicable.
: We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.
: P.A. Ascierto has/had a consultant/advisory role for Bristol Myers-Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Amgen, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune. He also received Research funds from Bristol Myers-Squibb, Roche-Genentech, Array.Antonio M. Grimaldi received honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis and Roche Genentech, and had consultant/advisory role for Merck Sharp & Dohme and Novartis.E. Simeone participated to advisory board for Bristol-Myers Squibb and received honoraria from Bristol-Myers Squibb, Novartis and Merck Sharp & Dohme.G. Palmieri has advisory role for Incyte, MSD, Novartis, Pierre-Fabre.All the other authors have no conflict of interest to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.